Source: PURDUE UNIVERSITY submitted to NRP
IDENTIFYING AND CHARACTERIZING YEAST EPIGENETIC FACTORS IN ANTIFUNGAL DRUG RESISTANCE
Sponsoring Institution
National Institute of Food and Agriculture
Project Status
COMPLETE
Funding Source
Reporting Frequency
Annual
Accession No.
1007570
Grant No.
(N/A)
Cumulative Award Amt.
(N/A)
Proposal No.
(N/A)
Multistate No.
(N/A)
Project Start Date
Dec 8, 2015
Project End Date
Sep 30, 2020
Grant Year
(N/A)
Program Code
[(N/A)]- (N/A)
Recipient Organization
PURDUE UNIVERSITY
(N/A)
WEST LAFAYETTE,IN 47907
Performing Department
Biochemistry
Non Technical Summary
Animal, plant, and human fungal pathogens are a major world-wide concern for production agriculture and human health1-4. A significant complication in treating plants, animals, and humans with fungal diseases has been the development of drug resistant fungi2-4. With the limited number of effective antifungal drugs and fungicides, treatment and fungal drug resistance is a major concern for agricultural economics, the global food supply, and human health. Because of these global issues and the development of fungal resistance to antifungal drugs or fungicides, there is a critical need to fully understand how yeast/fungi develop drug resistance and to identify novel targets for antifungal drugs.The proposed research is important because we have determined for the first time that SET domain-containing epigenetic factors impact the efficacy of antifungal drugs. This represents a new approach to understanding antifungal drug resistance by identifying, characterizing and determining that SET domain-containing proteins control genes needed for antifungal drug resistance. Moreover, our experiments may uncover new pathways that govern antifungal drug resistance. Using our expertise in epigenetics, biochemistry, molecular biology, and genetic analyses, we are in the unique position to characterize how these epigenetic factors play a role in antifungal drug resistance. The significance of our work is that we will have a positive impact on the scientific field of epigenetics/chromatin field as well as human health and production agriculture. The potential outcome of our research is the future development of novel anti-fungal drug targets that benefit society.
Animal Health Component
(N/A)
Research Effort Categories
Basic
100%
Applied
(N/A)
Developmental
(N/A)
Classification

Knowledge Area (KA)Subject of Investigation (SOI)Field of Science (FOS)Percent
2124020104040%
7234020104060%
Goals / Objectives
Determine how Set4 expression is regulated.Define the biochemical function of Set4.Identify gene targets of Set4.Identify suppressors for the set4deltaazole-resistant phenotype.
Project Methods
Objective 1. Determine how Set4 expression is regulated. Our preliminary data show that Set4 is not expressed under standard untreated growth conditions. However, Set4 is expressed when treated with ketoconazole. To our knowledge, this is the first report of an inducible SET domain-containing protein.To understand how the SET4 gene is regulated, we will use genetics and ChIP analysis to identify transcription factor(s) and repressor(s) responsible for controlling Set4 expression. Using the Yeastract curated repository of regulatory association between transcription factors and target genes in S. cerevisiae, 25 known transcription factors and repressors, including the transcription factor Upc2 and repressor Mot3, have been identified as potentially targeting the SET4 promoter. ChIP and quantitative Real-Time PCR (qRT-PCR) analysis will be used to determine if Upc2 directly targets SET4's promoter. To determine if Mot3 is a repressor for SET4, a mot3D strain will be treated with ketoconazole and SET4 expression will be analyzed by qRT-PCR. ChIP and qRT-PCR analysis will be used to determine if Mot3 directly targets SET4's promoter. Overall, understanding how SET4 expression is regulated will help us understand how cells develop resistant to azoles and also identify additional factors that alter the efficacy of antifungal drugs.Objective 2. Define the biochemical function of Set4. Currently, no biochemical studies have been published on Set4. However, because we have identified the condition when Set4 is expressed and shown it can associate with chromatin, we are in the unique position to biochemically characterize Set4. Because Set4 contains a conserved SET domain, a known catalytic domain for many methyltransferases, we will determine if Set4 has intrinsic histone methyltransferase activity. In addition, because Set3, a paralog of Set4, is in a protein complex with HDACs, we will determine if Set4 is in a similar complex that has an associated HDAC activity.Histone methyltransferase assays will be performed using isolated Set4-3XFLAG tagged protein from yeast, S-adenosyl-L-[methyl-3H] methionine as the cofactor (methyl donor), and various histone substrates (i.e., free histones, nucleosomes, yeast chromatin and histone peptides). Aliquots of this reaction will be spotted to p81 Whatman filters, and amount of 3H-methyl incorporation on histone substrates will be determined by scintillation counting. Identical aliquots will be separated by SDS-PAGE, stained with Coomassie blue to verify equal loading and fluorographed to identify which histone is methylated. To determine if Set4 associates with a HDAC(s), Set4-3XFLAG tagged protein from yeast will be isolated and analyzed for HDAC activity using fluorescently label histone peptides. Alternatively, tritium labelled histones or nucleosomes could be used as substrates for the HDAC assay. If HDAC activity is detected, mass spectrometry analysis will be used to identify the associated HDAC(s) proteins. Mass spectrometry analysis will be done in collaboration with a departmental colleague Dr. Mark Hall, Purdue University, Department of Biochemistry. Overall, completion of this aim will provide the first insights into how Set4 biochemically functions to control epigenetic gene expression and resistance to antifungal drugs. If no methyltransferase activity is detected on histones, an unbiased approach will be used to determine with Set4 methylates non-histone substrates.Objective 3.Identify gene targets of Set4. Our preliminary data show that yeast cells lacking SET4 are resistant to ketoconazole and that Set4 expression is induced upon treatment with ketoconazole. Furthermore, our preliminary data suggest that deletion of SET4 does not affect the expression of ERG11, ERG3, PDR5, PDR11, and UPC2 which are known genes involved in azole drug resistance. Based on these observations and our preliminary data showing Set4 associates with chromatin, we hypothesize that Set4 is needed to repress novel genes needed for antifungal drug resistance.To identify Set4 regulated genes that confer antifungal drug resistance, we will perform genome-wide microarray analysis of set4deltaand BY4741 cells treated with and without ketoconazole. RNA will be labeled for hybridization on an Agilent yeast microarray Hybridization, labeling of RNA, and data processing will be done in collaboration with Dr. Jennifer Freeman (School of Health Sciences, Purdue University) using Agilent microarray technology. Dr. Freeman's expertise and collaborative support will ensure that this aim is successful. All gene expression changes will be validated by standard gene expression qRT-PCR analysis. In addition, ChIP analysis will be used to show that the affected genes are direct targets of Set4. The efficacy of antifungal drugs on all genes identified in the microarray and ChIP assays will be analyzed.Objective 4. Identify suppressors for the set4deltaazole-resistant phenotype. Our preliminary data show that cells lacking SET4 are resistant to ketoconazole while cells lacking SET1 and SET3 grow slower in the presence of ketoconazole indicating for the first time that SET domain-containing proteins and this class of epigenetic factors govern the efficacy of antifungal drugs. Therefore, we hypothesize that loss of genes that result in hypersensitivity to azole drug resistance will suppress the set4deltaazole-resistant phenotype.To identify suppressors of the set4deltaazole-resistant phenotype, candidate approaches and synthetic genetic array analysis will be used to identify genes. Candidate approach: Double deletion strains will be generated by deleting SET1 or SET3 in a set4deltabackground. The efficacy of antifungal drugs on set1Dset4deltaand set3Dset4deltastrains will be tested by standard dose curve analysis. Unbiased approach: A set4deltastrain will be crossed with the entire yeast ORF deletion strain collection to generate double deletions. The efficacy of antifungal drugs on all viable double deletion strains will be determined by standard dose curve analysis. Dr. Tony Hazbun (Purdue University, Department of MCMP) will provide advice and assistance.Overall, we expect Set1, Set3 and other suppressors will help us identify a pathway for antifungal drug resistance. These suppressors could be excellent candidates for the development of antifungal drugs. This aim would provide the rationale to further study Set1 and Set3 and determine if these epigenetic factors can alter the efficacy of antifungal drugs on drug resistant pathogenic fungi. For example, we can determine if drug resistant fungi expressing Upc2 activating mutations are more sensitive to antifungal drugs when SET1 and/or SET3 are deleted.

Progress 12/08/15 to 09/30/20

Outputs
Target Audience:General Scientific Community - National and International General Public - Local, State, and National Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?This project has led to the training and professional development of fourgraduate students Nina Serratore, Kortany Baker, Debasmita Saha and Smriti Hoda. These students received training in performing, writing and commutating our results as a publication and at conferences. They also developed abilities to critically analyze results. Nina Serratore also graduated with her PhDand obtained a job in industry. In addition, this project also trained fourundergraduate students. Theirwork will contributeto a published manuscript. In addition, they attend laboratory meetings and they also have to write a written report at the end of each semester. They also can obtain summer and academic fellowships to perform paidresearch in the lab and for professional development for research or medical careers. How have the results been disseminated to communities of interest?Our results of this project havebeen published. In addition, our work has also been presented at a scientific conference (Candida and Candidiasis Conference). Our work would have been presented at other scientific conference but due to Covid19 all conferences where cancelled. What do you plan to do during the next reporting period to accomplish the goals? Nothing Reported

Impacts
What was accomplished under these goals? For this project we accomplished a majority if not all of the goals. Goal 1: We determined that Set4 expression is induced by the sterol sensing transcriptional activators, Upc2 and Ecm22 under hypoxic conditions and was published in Genetics in 2018 (Serratore 2018). Goal 2 was also published (Serratore 2018) where we determine that Set4 functions as a corepressor for the Hap1 transcription factor to repress ergosterol biosynthesis genes under anaerobic growth conditions. Goal 3 we determined by RNA-sequencing analysis and chromatin immunoprecipitation that Set4 targets ERG genes under anaerobic conditions and is recruited to these genes by the Hap1 transcription factor. We also demonstrate that Set4 expression is upregulated in an erg3 deletion strain suggesting a precursor sterol, but not ergosterol, regulates Set4 levels. Overall, we have discovered a new sterol-Upc2 signaling pathway mediated by Set4 that governs azole drug efficacy and sterol homeostasis under hypoxic conditions. These observations were published in Genetics (Serratore 2018). Goal 4: We have generated spontaneous suppressors for genomic mutations when Set4 is overexpressed. We will be sequencing these strains for identification of the suppressor mutations. We are also characterizing the role of Set1, Set4 and Hap1 in a human fungal pathogen Candida glabrata. Interesting, they all are necessary for ergosterol homeostasis upon azole drug treatment.

Publications

  • Type: Journal Articles Status: Accepted Year Published: 2020 Citation: Strahl BD and Briggs SD. The SAGA continues: The rise of cis- and trans-histone crosstalk pathways. Biochim Biophys Acta Gene Regul Mech. 2020 Jul 6:194600. doi: 10.1016/j.bbagrm.2020.194600.


Progress 10/01/18 to 09/30/19

Outputs
Target Audience:General Scientific Community - National and International General Public - Local, State, and National Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?This project has led to the training and professional development of two graduate student Kortany Baker and Smrithi Hoda. These students received training in performing, writing and commicating our results as a publication and at conferences. They also developed abilities to critically anazye results. Nina Serratore also graduated and obtained a job in industry. In addtion, this project also trained three undergraduate student which two willcontributed to a published manuscript to be submitted this semester. How have the results been disseminated to communities of interest?Our results of this project will be sumbitted for publication this semester. In addition, our work will also presented at a scientific conference (Candida and Candidiasis Conference, Montreal, Canada). What do you plan to do during the next reporting period to accomplish the goals?We also plan to published a manuscript this fall "The impact of H3H4 methylation and ergosterol homeostasis on antifungal azole drug resistance in Candida glabrata". In addition, next semester we plan to publish another paper on how epigenetics impact oxidative stress.

Impacts
What was accomplished under these goals? We accomplished various aspect of goals 1 and 3 of this project. Goal 1: We determined that Set4 expression is induced by the sterol sensing transcriptional activators, Upc2 and Ecm22 under hypoxic conditions. Goal 3: In addtion, we determined by RNA-sequencing analysis that Set4 is required for ERG gene repression. Importantly, we show that Set4 directly targets ergosterol gene promoters, ERG11 and ERG3 under hypoxia and that Set4 recruitment is dependent on the transcriptional repressor, Hap1. Finally, we demonstrate that Set4 expression is upregulated in an erg3 deletion strain suggesting a precursor sterol, but not ergosterol, regulates Set4 levels. Overall, we have discovered a new sterol-Upc2 signaling pathway mediated by Set4 that governs azole drug efficacy and sterol homeostasis under hypoxic conditions. These observations were published in Genetics (2018). Goal 2: We are continuing to determine the biochemical function/methyltranferase function of Set4 and Set1. Goal 4: We will sequence our spontaneous suppressors for genomic mutations when Set4 is overexpressed. We are also characterizing the role of Set1, Set4 and Hap1in a human funal pathogen Candida glabrata.

Publications


    Progress 10/01/17 to 09/30/18

    Outputs
    Target Audience:General Scientific Community - National and International General Public - Local, State, and National Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?This project has led to the training and professional development of two graduate student Nina Serratore and Kortany Backer. These students received training in performing, writing and commicating our results as a publication and at conferences. They also developed abilities to critically anazye results. Nina Serratore also graduated and obtained a job in industry. In addtion, this project also trained three undergraduate student which also contributed to pur published manuscript. How have the results been disseminated to communities of interest?Our results of this project have published in Genetics, a peer-reviewed science journal. In addition, our work was also presented at a scientific conference (14th ASM Candida and Candidiasis Conference). What do you plan to do during the next reporting period to accomplish the goals?We plan to have our manuscript published "Determining how Set1 interacts with RNA polymerase." We also plan to published an additional manuscript "The impact of H3H4 methylation and ergosterolhomeostasis on antifungal azole drug resistance in Candida glabrata"

    Impacts
    What was accomplished under these goals? We accomplished various aspect of goals 1 and 3 of this project. Goal 1: We determined that Set4 expression is induced by the sterol sensing transcriptional activators, Upc2 and Ecm22 under hypoxic conditions. Goal 3: In addtion, we determined by RNA-sequencing analysis that Set4 is required for ERG gene repression. Importantly, we show that Set4 directly targets ergosterol gene promoters, ERG11 and ERG3 under hypoxia and that Set4 recruitment is dependent on the transcriptional repressor, Hap1. Finally, we demonstrate that Set4 expression is upregulated in an erg3 deletion strain suggesting a precursor sterol, but not ergosterol, regulates Set4 levels. Overall, we have discovered a new sterol-Upc2 signaling pathway mediated by Set4 that governs azole drug efficacy and sterol homeostasis under hypoxic conditions. These observations were published in Genetics (2018). Goal 2: We are still continuing to determine the biochemical function/methyltranferase function of Set4. Goal 4: Currently, we have identified spontaneous suppress when Set4 is overexpressed. These suppressors are being evaulated biochemically and for genomic mutations.

    Publications

    • Type: Journal Articles Status: Published Year Published: 2018 Citation: Serratore, N.D., Baker, K.M., Macadlo, L.A., Gress, A.R., Powers, B.L., Atallah, N., Westerhouse K.M., Hall, M.C., Weake, V.M., Briggs, S.D. A Novel Sterol-Signaling Pathway Governs Azole Antifungal Drug Resistance and Hypoxic Gene Repression in Saccharomyces cerevisiae. Genetics. 208: 1037-1055, 2018. doi: 10.1534/genetics.117.300554.


    Progress 10/01/16 to 09/30/17

    Outputs
    Target Audience:General Scientific Community - Nationally and Internationally General Public - Local, State, and National Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?This project has led to the training and professional development of two graduate students Nina Serratore and Kortany Baker. These students received training in performing, writing and commicating our results as amanuscript under and at conferences. They also developed abilities to critically anazye results. In addtion, this project also trained three undergraduate students which also contributed to authorship on a manuscript. How have the results been disseminated to communities of interest?Our results of this project will be published in peer-reviewed science journals. In addition, our work will also be presented at scientific conferences. What do you plan to do during the next reporting period to accomplish the goals?We plan to have our manuscript published"Sterol facilitated induction of Set4 governs antifungal drug efficacy and mediates epigenetic changes under hypoxic conditions in Saccharomyces cerevisiae".We also plan to published an additional manuscript "Determining how Set1 interacts with RNA polymerase."

    Impacts
    What was accomplished under these goals? We accomplished various aspect of goals 1 and 3of this project. Goal 1: Wedetermined that Set4 expression is induced by the sterol sensing transcriptional activators, Upc2 and Ecm22. Goal 3: In addtion, we determined by RNA-sequencing analysis that Set4 is required for ERG gene repression. Importantly, we show that Set4 directly targets ergosterol gene promoters, ERG11 and ERG3 under hypoxia and that Set4 recruitment is dependent on the transcriptional repressor, Hap1. Finally, we demonstrate that Set4 expression is upregulated in an erg3? strain suggesting a precursor sterol, but not ergosterol, regulates Set4 levels. Overall, we have discovered a new sterol-Upc2 signaling pathway mediated by Set4 that governs azole drug efficacy and sterol homeostasis under hypoxic conditions.

    Publications

    • Type: Journal Articles Status: Published Year Published: 2017 Citation: Zhang, Y., Serratore, N.D., and Briggs, S.D. N-ICE plasmids for generating N-terminal 3?�?FLAG tagged genes that allow inducible, constitutive or endogenous expression in Saccharomyces cerevisiae. Yeast. 34: 223-235, 2017.


    Progress 12/08/15 to 09/30/16

    Outputs
    Target Audience:General Scientific Community -- Nationally and Internationally General Public - Local, State, and Nationally Changes/Problems: Nothing Reported What opportunities for training and professional development has the project provided?This project has led to the training and professional development of two graduate students Nina Serratore andYueping Zhang. These students received training in performing, writing and commicating our results as a publication and at conferences. They also developed abilities to critically anazye results. In addtion, this project also trained two undergraduate students. How have the results been disseminated to communities of interest?Our results of this project will be published in peer-reviewed sciencejournals. In addition,our work has also been presented at scientific conferences. What do you plan to do during the next reporting period to accomplish the goals?We plan to have our manuscript published "N-ICE plasmids for generating N-terminal 3×FLAG tagged genes that allow Inducible, Constitutive, or Endogenous expression in Saccharomyces cerevisiae." We also plan to published two additional manuscripts: Manuscript 1) Determining how Set1 interacts with RNA polymerase and 2) Determining the biological and biochemical function of Set4.

    Impacts
    What was accomplished under these goals? One of the goals that was accomplished was the development of a newplasmids and methodto tag proteins in yeast. We have constructed the N-ICE plasmid system for PCR-based N-terminal 3×FLAG epitope tagging of non-essential and essential genes under the control an Inducible promoter (GAL1), Constitutive promoters (CYC1 or PYK1), or the Endogenous promoter. Our N-ICE plasmid system also provides the option of three different selection markers, including KanMX, HphMX, and NatMX cassettes. In addition, the integrated selection marker and the heterologous promoter can be excised with a subsequent step using Cre recombinase, leaving the target gene expressed from the endogenous promoter. This system can also be applied to tagging essential genes expressed by their endogenous promoters. We have validated the N-ICE system by N-terminal tagging two non-essential genes (SET1 and SET2) and two essential genes (ERG11 and PKC1). Overall, the N-ICE plasmid system will provide valuable new tools to enhance the yeast epitope tagging toolbox.These new "N-ICE" plasmids were constructed so that non-essential and essential genes can be N-terminally 3×FLAG tagged and expressed from an Inducible promoter (GAL1), Constitutive promoters (CYC1 or PYK1), or the Endogenous promoter. The second goal that was accomplished was determining how Set1 interacted with RNA Polymerase II.Currently, this work is being writteninto a manuscript which we hope to have published next year. The other goals which are still in progress are determining how Set4 is regulated, Defining the biochemical function of Set4, Identification of Set4 target genes, and identification of suppressors for azole resistant strains. These remaining goals are still ongoing in the laboratory.

    Publications

    • Type: Journal Articles Status: Submitted Year Published: 2017 Citation: Zhang, Y., Serratore, N.D., Briggs, S.D. N-ICE plasmids for generating N-terminal 3�FLAG tagged genes that allow Inducible, Constitutive, or Endogenous expression in Saccharomyces cerevisiae. Submitted and underreview 2016